Merck & Co to buy immunology specialist Prometheus
$10.8 billion cash deal give Merck rights to late-stage candidate for two inflammatory bowel conditions
Merck & Co has agreed to buy Prometheus Biosciences, which specialises in developing treatments for immune-modulated diseases, for $10.8 billion (£8.7 billion) in cash.